Rigel Pharmaceuticals Inc
A South San Francisco biotechnology company that develops and sells prescription medicines for blood disorders and cancer. Its FDA-approved drugs include Tavalisse for immune thrombocytopenia (a low blood-platelet condition) and Rezlidhia for a form of acute myeloid leukemia. Founded in 1996, the company shares its name with Rigel, a brilliant blue star in the Orion constellation whose Arabic name means "the foot of the giant."
Granted 1.17M · Bought 1.00M · Sold 82.6K
Granted 75.0K
Granted 372.2K · Sold 21.8K
Granted 50.0K
Granted 50.0K · Sold 5.4K
Granted 378.1K · Sold 23.8K
Granted 50.0K
Granted 248.2K · Sold 2.8K
Granted 38.6K
Granted 87.3K · Sold 4.0K
Granted 83.3K
Granted 83.3K
Granted 83.3K
Granted 77.0K · Sold 5.0K
Granted 7.0K
Granted 5.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rodriguez Raul RCEO, President, Director · 22 transactions | +61.1% | 279.6K | 1.17M | 1.00M | 82.6K |
| Kotzin Brian L.Director · 3 transactions | +300% | 100.0Kas of May 2024 | 75.0K | — | — |
| Schorno Dean LEVP & Chief Financial Officer · 18 transactions | +57.6% | 78.8K | 372.2K | — | 21.8K |
| Lyons Gary ADirector · 2 transactions | +200% | 75.0Kas of May 2023 | 50.0K | — | — |
| Dummer WolfgangEVP & CMO · 2 transactions | — | 72.5Kas of Feb 2023 | 50.0K | — | 5.4K |
| Santos David AEVP, Chief Commercial Officer · 13 transactions | — | 62.0K | 378.1K | — | 23.8K |
| Vance DollyEVP Corp. Affairs, G.C., Sect. · 1 transaction | +10380% | 60.3Kas of Jan 2022 | 50.0K | — | — |
| Furey Raymond J.EVP, GC, CCO & Corp Sec · 8 transactions | — | 50.9K | 248.2K | — | 2.8K |
| Rojkjaer LisaEVP, Chief Medical Officer · 4 transactions | — | 34.0K | 38.6K | — | — |
| Moos Walter HDirector · 7 transactions | -32.1% | 18.5K | 87.3K | — | 4.0K |
| Lapointe Anthony GreggDirector · 5 transactions | -27% | 18.3K | 83.3K | — | — |
| Wasman JaneDirector · 5 transactions | -27% | 18.3K | 83.3K | — | — |
| Hannah Alison L.Director · 5 transactions | +162% | 16.4K | 83.3K | — | — |
| Ali-Jackson KamilDirector · 7 transactions | — | 10.1K | 77.0K | — | 5.0K |
| Frohlich Mark WDirector · 2 transactions | — | 7.0K | 7.0K | — | — |
| Miller Michael PatrickDirector · 1 transaction | — | 5.9K | 5.8K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 5 years: +854.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.